Cronos to acquire CanAdelaar for up-front cash consideration of US$67.0M 1 plus cash earnout of 0.5x normalized EBITDA in 2026 and 2027 Up-front consideration represents approximately 1.4x CanAdelaar LTM revenue and 2.4x LTM EBITDA 2 Will give Cronos #1 market share 3 in the largest adult-use cannabis market in Europe Enables borderless product strategy, leveraging investments in genetics, R&D, and product development... Read More
